...
首页> 外文期刊>Medicinal Chemistry >Flexible Estrogen Receptor Modulators: Synthesis, Biochemistry and Molecular Modeling Studies for 3-Benzyl-4,6-diarylhex-3-ene and 3,4,6-Triarylhex-3-ene Derivatives
【24h】

Flexible Estrogen Receptor Modulators: Synthesis, Biochemistry and Molecular Modeling Studies for 3-Benzyl-4,6-diarylhex-3-ene and 3,4,6-Triarylhex-3-ene Derivatives

机译:柔性雌激素受体调节剂:3-苄基-4,6-二芳基己烯-3-烯和3,4,6-三芳基己烯-3-烯衍生物的合成,生物化学和分子模型研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Selective estrogen receptor modulators (SERMs) such as tamoxifen and toremifene are clinically useful drugs in the endocrine treatment of estrogen receptor positive breast cancer while raloxifene is an effective intervention for osteoporosis. In an ongoing SERM discovery programme we now report the synthesis of a series of 3-benzyl-4,6-diarylhex- 3-enes and 3,4,6-triarylhex-3-enes containing an extended flexible core structure. In these novel structures, the ethylene group acts as a flexible spacing group linking the aryl Ring A or Ring B with the core alkene group. In the benzyl-4,6- diarylhex-3-ene series an additional methylene group is inserted as a spacing group between the aryl ring C and the ethylene core group. These products demonstrated antiproliferative activity against the MCF-7 human breast cancer cell line. The alkene compounds were also shown to have binding affinity for the estrogen receptor alpha (IC50 values for the most active compounds in the range 0.110-0.293?M) together with selectivity for ER / . The compounds demonstrated antiestrogenic activity in Ishikawa cells with low estrogenic stimulation. The structure-activity relationships for the active ligands were further explored in a computational study where docked structures of the active compounds were compared with the X-ray crystal structures for the complexes of ER with 4-hydroxytamoxifen and ER with raloxifene. The alignment of the aromatic rings B and C of the compounds within the ligand binding domain could then be correlated with their observed ER / selectivity.
机译:诸如他莫昔芬和托瑞米芬的选择性雌激素受体调节剂(SERM)是内分泌治疗雌激素受体阳性乳腺癌的临床有用药物,而雷洛昔芬是骨质疏松症的有效干预措施。现在,在正在进行的SERM发现计划中,我们报告了一系列含有扩展的柔性核结构的3-苄基-4,6-二芳基己烯-3-烯和3,4,6-三芳基己烯-3-烯的合成。在这些新颖的结构中,亚乙基作为连接芳基环A或环B与核心烯基的柔性间隔基团。在苄基-4,6-二芳基己烯-3-烯系列中,在芳环C和亚乙基核基团之间插入一个额外的亚甲基作为间隔基团。这些产品对MCF-7人乳腺癌细胞系显示出抗增殖活性。还显示出该烯烃化合物对雌激素受体α具有结合亲和力(最具活性的化合物的IC50值在0.110-0.293?M范围内)以及对ER /的选择性。所述化合物在具有低雌激素刺激的石川细胞中显示出抗雌激素活性。在计算研究中进一步探讨了活性配体的构效关系,其中将活性化合物的对接结构与ER与4-羟基他莫昔芬和ER与雷洛昔芬的配合物的X射线晶体结构进行了比较。然后可以将化合物在配体结合域内的芳环B和C的排列与其观察到的ER /选择性相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号